Navigating Systemic Therapy Options in HER2+ Breast Cancer

Panelists discuss a high-level overview of systemic therapies for advanced HER2+ breast cancer, outlining the roles of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) in treatment, as well as treatment strategies for patients with brain metastases. They also explore the shared decision-making process that informed the recommendation of the HER2CLIMB regimen.

EP: 1.Overview of HER2 Breast Cancer

EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians

EP: 3.HER2+ Breast Cancer Diagnosis: Insights fFrom Patients and Clinicians

EP: 4.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach

EP: 5.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective

EP: 6.Tailoring Patient Education and Resources in HER2+ Breast Cancer

EP: 7.Navigating HER2+ Breast Cancer Treatment: A Patient's Journey

Now Viewing

EP: 8.Navigating Systemic Therapy Options in HER2+ Breast Cancer

EP: 9.Key Insights from the HER2CLIMB Trial

1. Dr Iyengar: Please provide a high-level overview of the systemic therapies that you consider for advanced HER2+ breast cancer. (sSee NCCN Guidelines Version 2.2024.)
   1. What is the role of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and ADCs in treating advanced HER2+ breast cancer?
   2. How do you typically manage treat patients with advanced HER2+ breast cancer and brain metastases?
   3. Following Dorian’s evaluation, how did the shared decision-making process unfold, and what factors ultimately led you to recommend the HER2CLIMB regimen (trastuzumab [Herceptin] and + tucatinib [Tukysa] and capecitabine [Xeloda])?

Recent Videos